Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuromodulation Market: Innovation Brings High-Growth Rewards

Executive Summary

You may also be interested in...



Neuromodulation 2015: Innovation Expands Opportunities In Chronic Pain

In the market for neuromodulation devices, the largest opportunity is in the treatment of chronic pain, a condition that affects more than 1.5 billion people worldwide. Innovation is driving growth in this sector as companies develop next-generation neuromodulation technologies designed to improve outcomes, and resolve some of the problems with existing devices; these technologies will significantly expand the treatable population, and will allow companies both large and small to capture market share based on device efficacy and the strength of clinical evidence.

Targeting The Tongue: Helius Medical’s Unique Approach To Neuromodulation Tested In Trials

Neuromodulation start-up Helius Medical Technologies is employing a simpler, more primal connection to send potentially therapeutic signals to the brain – the tongue. The company is entering pivotal clinical trials to test the technology in select patients with traumatic balance disorder and traumatic brain injury, and evaluating the device for use in patients with multiple sclerosis.

NeuroTherm Buy Boosts St. Jude’s Pain Business

NeuroTherm makes devices for radiofrequency ablation of nerves in painful facet joints in the neck or back to treat chronic pain. Although it markets neurostimulators, St. Jude currently does not sell any devices in the radio-frequency ablation segment of the pain-therapy market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel